Berron Diagnostics is developing a rapid, point-of-care diagnostic platform designed to bypass standard days-long bacterial cultures. We are building technology to empower immediate, targeted prescribing.
Physicians currently have no way to identify the exact pathogen at the point of care. This leads to a cascade of clinical and economic consequences, creating a massive opportunity for rapid diagnostic disruption.
Physicians are forced to prescribe broad-spectrum antibiotics without knowing the specific pathogen or its resistance profile.
Lab cultures take 48–72 hours. Patients are mid-treatment with potentially ineffective antibiotics before results arrive.
60% of women experience at least one UTI. Misdiagnosis drives recurrence, patient dissatisfaction, and skyrocketing healthcare costs.
Antibiotic overuse accelerates antimicrobial resistance (AMR) — a silent pandemic. UTIs are a leading driver of this global threat.
We are currently operating in stealth mode to protect our core intellectual property. If you are an accredited investor, venture capital firm, or strategic partner, please reach out to schedule a meeting and request our confidential pitch deck.